A Phase 3 interventional study of adalimumab in Ulcerative Colitis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-07.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 10 in phase 3, and was the 4th registered.
1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 592 is above the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 152 across the 18 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
53 studies in Colitis, Ulcerative by AbbVie: 6 open now, 13 under way, 5 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 9th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2007, is one of 19 in phase 3, and was the 5th registered.
AbbVie’s Colitis, Ulcerative studies by the year they started, since 2000.
1 of the studies testing adalimumab in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
To assess the long-term safety and maintenance of response of adalimumab in subjects with ulcerative colitis who participated in and successfully completed M06-826 (NCT00385736) or M06-827 (NCT00408629).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
Biological: adalimumab
adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
Also known as: ABT-D2E7, HUMIRA
Partial Mayo Score: Change From Baseline Over Time
The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Partial Mayo score indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Mayo Score: Change From Baseline Over Time
The Mayo score ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo score indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Percentage of Participants With Remission Per Partial Mayo Score Over Time
The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). Remission was defined as Partial Mayo score ≤ 2 with no subscore \> 1.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Mayo Endoscopy Subscore: Change From Baseline Over Time
The Mayo Endoscopy subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Endoscopy subscore indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Mayo Rectal Bleeding Subscore: Change From Baseline Over Time
The Mayo Rectal Bleeding subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Rectal Bleeding subscore indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Mayo Physician's Global Assessment of Disease Severity Subscore: Change From Baseline Over Time
The Mayo Physician's Global Assessment of Disease Severity subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Physician's Global Assessment of Disease Severity subscore indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Mayo Stool Frequency Subscore: Change From Baseline Over Time
The Mayo Stool Frequency subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Stool Frequency subscore indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Inflammatory Bowel Disease Questionnaire (IBDQ): Change From Baseline Over Time
The IBDQ is a 32-item questionnaire that assesses how the subject felt during the 2 weeks before the measurement time point. Questions are related to symptoms the subject might have had as a result of UC, how the subject felt in general, how the subject's mood was, and social and work problems the subject might have that resulted from UC. An increase in IBDQ score indicates less impact of UC on the subject's life. The responses to each question range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
36-Item Short Form Health Survey Version 2 (SF-36) Mental Component Score: Change From Baseline Over Time
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
36-Item Short Form Health Survey Version 2 (SF-36) Physical Component Score: Change From Baseline Over Time
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Work Productivity and Activity Impairment: General Health Version 2.0 (WPAI:GH) Work Time Missed Because of Ulcerative Colitis: Change From Baseline Over Time
The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
WPAI:GH Impairment While Working: Change From Baseline Over Time
The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
WPAI:GH Overall Work Impairment: Change From Baseline Over Time
The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
WPAI:GH Activity Impairment: Change From Baseline Over Time
The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
Time frame: Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Colectomy Rate
The colectomy rates were estimated using Kaplan-Meier methodology based on the time to first colectomy.
Time frame: 5 years
Health Care Resource Utilization (HCRU): Cumulative Number of Unscheduled Utilizations
The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to ulcerative colitis since the last visit. The cumulative number of unscheduled utilizations over the course of the study is presented.
Time frame: 5 years
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
Time frame: From first dose of study drug until 70 days after the last dose of study drug (up to 398 weeks)
Hematology: Mean Change From Baseline to Final Values in Hemoglobin
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
Time frame: Baseline (Week 0), final value (up to 5 years)
Hematology: Mean Change From Baseline to Final Values in Hematocrit
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
Time frame: Baseline (Week 0), final value (up to 5 years)
Hematology: Mean Change From Baseline to Final Values in Red Blood Cell Count, Platelet Count, White Blood Cell Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
Time frame: Baseline (Week 0), final value (up to 5 years)
Clinical Chemistry: Mean Change From Baseline to Final Values in Alanine Aminotransferase, Aspartate Aminotransferase, and Alkaline Phosphatase
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
Time frame: Baseline (Week 0), final value (up to 5 years)
Clinical Chemistry: Mean Change From Baseline to Final Values in Total Bilirubin, Creatinine, and Uric Acid
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
Time frame: Baseline (Week 0), final value (up to 5 years)
Clinical Chemistry: Mean Change From Baseline to Final Values in Blood Urea Nitrogen, Inorganic Phosphate, Calcium, Sodium, Potassium, Glucose, Cholesterol, and Triglycerides
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
Time frame: Baseline (Week 0), final value (up to 5 years)
Clinical Chemistry: Mean Change From Baseline to Final Values in Albumin and Total Protein
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
Time frame: Baseline (Week 0), final value (up to 5 years)
Clinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
Time frame: Baseline (Week 0), final value (up to 5 years)
| Milestone | Adalimumab 40 mg EOW/EW |
|---|---|
| Started | 585 |
| Completed | 255 |
| Not completed | 330 |
| Withdrew: Adverse event | 81 |
| Withdrew: Withdrew consent | 90 |
| Withdrew: Lost to follow-up | 13 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Lack of efficacy | 94 |
| Withdrew: Other | 46 |
The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Partial Mayo score indicates improvement.
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 2.5 ± 2.02 |
| Change from Baseline to Week 48 | -0.2 ± 2.04 |
| Change from Baseline to Week 96 | -0.4 ± 1.78 |
| Change from Baseline to Week 144 | -0.5 ± 2.06 |
| Change from Baseline to Week 192 | -0.6 ± 1.84 |
| Change from Baseline to Week 240 | -0.8 ± 1.79 |
| Change from Baseline to Week 292 | -0.7 ± 2.05 |
| Change from Baseline to Week 340 | -1.0 ± 1.97 |
| Change from Baseline to Week 388 | -2.0 ± 1.00 |
The Mayo score ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding, endoscopy, and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo score indicates improvement.
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 3.5 ± 2.72 |
| Change from Baseline to Week 48 | -0.3 ± 2.64 |
| Change from Baseline to Week 96 | -0.5 ± 2.49 |
| Change from Baseline to Week 144 | -0.8 ± 2.73 |
| Change from Baseline to Week 192 | -0.8 ± 2.52 |
| Change from Baseline to Week 240 | -1.0 ± 2.40 |
| Change from Baseline to Week 292 | -0.9 ± 2.84 |
| Change from Baseline to Week 340 | -1.3 ± 2.87 |
| Change from Baseline to Week 388 | -2.0 ± 1.73 |
The Partial Mayo score (Mayo score without endoscopy) ranges from 0 (normal or inactive disease) to 9 (severe disease) and is calculated as the sum of 3 subscores (stool frequency, rectal bleeding and physician's global assessment \[PGA\]), each of which ranges from 0 (normal) to 3 (severe disease). Remission was defined as Partial Mayo score ≤ 2 with no subscore \> 1.
| percentage of participants | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 52.4 |
| Week 48 | 61.2 |
| Week 96 | 69.3 |
| Week 144 | 75.0 |
| Week 192 | 74.7 |
| Week 240 | 77.2 |
| Week 292 | 76.7 |
| Week 340 | 73.9 |
| Week 388 | 100 |
The Mayo Endoscopy subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Endoscopy subscore indicates improvement.
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 1.1 ± 0.94 |
| Change from Baseline to Week 48 | -0.1 ± 0.95 |
| Change from Baseline to Week 96 | -0.1 ± 1.02 |
| Change from Baseline to Week 144 | -0.2 ± 0.93 |
| Change from Baseline to Week 192 | -0.3 ± 0.98 |
| Change from Baseline to Week 240 | -0.3 ± 0.97 |
| Change from Baseline to Week 292 | -0.3 ± 1.03 |
| Change from Baseline to Week 340 | -0.3 ± 1.18 |
| Change from Baseline to Week 388 | 0.0 ± 1.00 |
The Mayo Rectal Bleeding subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Rectal Bleeding subscore indicates improvement.
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 0.4 ± 0.68 |
| Change from Baseline to Week 48 | -0.1 ± 0.73 |
| Change from Baseline to Week 96 | -0.0 ± 0.63 |
| Change from Baseline to Week 144 | -0.1 ± 0.74 |
| Change from Baseline to Week 192 | -0.1 ± 0.69 |
| Change from Baseline to Week 240 | -0.2 ± 0.63 |
| Change from Baseline to Week 292 | -0.2 ± 0.76 |
| Change from Baseline to Week 340 | -0.2 ± 0.80 |
| Change from Baseline to Week 388 | -1.0 ± 1.00 |
The Mayo Physician's Global Assessment of Disease Severity subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Physician's Global Assessment of Disease Severity subscore indicates improvement.
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 0.8 ± 0.81 |
| Change from Baseline to Week 48 | -0.1 ± 0.89 |
| Change from Baseline to Week 96 | -0.2 ± 0.84 |
| Change from Baseline to Week 144 | -0.2 ± 0.89 |
| Change from Baseline to Week 192 | -0.2 ± 0.82 |
| Change from Baseline to Week 240 | -0.3 ± 0.82 |
| Change from Baseline to Week 292 | -0.2 ± 0.79 |
| Change from Baseline to Week 340 | -0.3 ± 0.88 |
| Change from Baseline to Week 388 | -0.7 ± 0.58 |
The Mayo Stool Frequency subscore ranges from 0 (normal) to 3 (severe disease). A negative change in Mayo Stool Frequency subscore indicates improvement.
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 1.3 ± 1.01 |
| Change from Baseline to Week 48 | -0.1 ± 0.89 |
| Change from Baseline to Week 96 | -0.2 ± 0.84 |
| Change from Baseline to Week 144 | -0.2 ± 0.89 |
| Change from Baseline to Week 192 | -0.2 ± 0.82 |
| Change from Baseline to Week 240 | -0.3 ± 0.86 |
| Change from Baseline to Week 292 | -0.3 ± 1.00 |
| Change from Baseline to Week 340 | -0.5 ± 0.99 |
| Change from Baseline to Week 388 | -0.3 ± 0.58 |
The IBDQ is a 32-item questionnaire that assesses how the subject felt during the 2 weeks before the measurement time point. Questions are related to symptoms the subject might have had as a result of UC, how the subject felt in general, how the subject's mood was, and social and work problems the subject might have that resulted from UC. An increase in IBDQ score indicates less impact of UC on the subject's life. The responses to each question range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 176.0 ± 34.45 |
| Change from Baseline to Week 48 | 2.1 ± 28.91 |
| Change from Baseline to Week 96 | 4.7 ± 28.73 |
| Change from Baseline to Week 144 | 5.2 ± 30.64 |
| Change from Baseline to Week 192 | 7.6 ± 28.66 |
| Change from Baseline to Week 240 | 11.2 ± 25.98 |
| Change from Baseline to Week 292 | 14.8 ± 27.36 |
| Change from Baseline to Week 340 | 14.6 ± 28.12 |
| Change from Baseline to Week 388 | 11.0 ± 12.53 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 47.1 ± 10.16 |
| Change from Baseline to Week 48 | -0.7 ± 9.61 |
| Change from Baseline to Week 96 | 0.3 ± 9.64 |
| Change from Baseline to Week 144 | 0.0 ± 9.52 |
| Change from Baseline to Week 192 | 0.1 ± 9.41 |
| Change from Baseline to Week 240 | 0.7 ± 7.86 |
| Change from Baseline to Week 292 | 1.8 ± 8.13 |
| Change from Baseline to Week 340 | 1.8 ± 6.81 |
| Change from Baseline to Week 388 | -7.3 ± 5.58 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.
| units on a scale | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 49.3 ± 8.06 |
| Change from Baseline to Week 48 | 0.7 ± 6.98 |
| Change from Baseline to Week 96 | 1.2 ± 6.26 |
| Change from Baseline to Week 144 | 1.1 ± 7.08 |
| Change from Baseline to Week 192 | 1.3 ± 7.46 |
| Change from Baseline to Week 240 | 2.2 ± 6.23 |
| Change from Baseline to Week 292 | 2.5 ± 7.03 |
| Change from Baseline to Week 340 | 3.0 ± 8.71 |
| Change from Baseline to Week 388 | 8.4 ± 2.00 |
The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
| percent of work time missed | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 4.5 ± 15.42 |
| Change from Baseline to Week 48 | 1.6 ± 24.04 |
| Change from Baseline to Week 96 | -0.2 ± 18.41 |
| Change from Baseline to Week 144 | 0.9 ± 20.19 |
| Change from Baseline to Week 192 | 0.2 ± 19.05 |
| Change from Baseline to Week 240 | -1.1 ± 17.21 |
| Change from Baseline to Week 292 | 8.2 ± 30.65 |
| Change from Baseline to Week 340 | 6.4 ± 24.96 |
| Change from Baseline to Week 388 | 0.0 ± 0.00 |
The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
| percent of work time impaired | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 16.7 ± 20.73 |
| Change from Baseline to Week 48 | 1.1 ± 22.45 |
| Change from Baseline to Week 96 | -1.9 ± 20.86 |
| Change from Baseline to Week 144 | -0.2 ± 24.11 |
| Change from Baseline to Week 192 | -2.9 ± 24.04 |
| Change from Baseline to Week 240 | -4.0 ± 21.40 |
| Change from Baseline to Week 292 | -3.8 ± 25.45 |
| Change from Baseline to Week 340 | -13.8 ± 26.04 |
| Change from Baseline to Week 388 | -15.0 ± 21.21 |
The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
| percent of overall work impairment | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 20.1 ± 24.30 |
| Change from Baseline to Week 48 | 1.2 ± 28.15 |
| Change from Baseline to Week 96 | -2.7 ± 24.99 |
| Change from Baseline to Week 144 | -0.8 ± 28.05 |
| Change from Baseline to Week 192 | -2.6 ± 26.69 |
| Change from Baseline to Week 240 | -5.0 ± 24.1 |
| Change from Baseline to Week 292 | 1.4 ± 35.53 |
| Change from Baseline to Week 340 | -7.3 ± 12.05 |
| Change from Baseline to Week 388 | -15.0 ± 21.21 |
The WPAI:GH questionnaire was used to assess work and activity impairment due to symptoms of ulcerative colitis in the last 7 days. The self-administered questionnaire measures the effect of the subject's health problems on work and daily activities in the previous week, specifically, the number of hours missed from work due to health problems, how much the subject's health problems affected work productivity, and how much the subject's health problems affected regular activities. Low scores indicate little or no impact of health problems on work and activities, and a negative change in the WPAI score indicates improvement.
| percent activity impaired | Adalimumab 40 mg EOW/EW |
|---|---|
| Baseline | 21.4 ± 24.00 |
| Change from Baseline to Week 48 | 1.1 ± 24.14 |
| Change from Baseline to Week 96 | -1.6 ± 21.80 |
| Change from Baseline to Week 144 | -0.7 ± 23.65 |
| Change from Baseline to Week 192 | -2.1 ± 20.91 |
| Change from Baseline to Week 240 | -3.4 ± 18.63 |
| Change from Baseline to Week 292 | -1.5 ± 19.79 |
| Change from Baseline to Week 340 | -9.6 ± 11.86 |
| Change from Baseline to Week 388 | -16.7 ± 15.28 |
The colectomy rates were estimated using Kaplan-Meier methodology based on the time to first colectomy.
| percentage of participants | Adalimumab 40 mg EOW/EW |
|---|---|
| Colectomy Rate | 3.88 |
The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to ulcerative colitis since the last visit. The cumulative number of unscheduled utilizations over the course of the study is presented.
| cumulative number of utilizations | Adalimumab 40 mg EOW/EW |
|---|---|
| Physician | 561 |
| Emergency Room | 43 |
| Hospital Admission | 65 |
| Days in Hospital | 435 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug. For more details on adverse events please see the Adverse Event section.
| Participants | Adalimumab 40 mg EOW/EW |
|---|---|
| Any TEAE | 496 |
| Any TESAE | 158 |
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
| g/L | Adalimumab 40 mg EOW/EW |
|---|---|
| Hematology: Mean Change From Baseline to Final Values in Hemoglobin | -0.1 ± 16.02 |
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
| Percentage of red blood cells | Adalimumab 40 mg EOW/EW |
|---|---|
| Hematology: Mean Change From Baseline to Final Values in Hematocrit | 0.013 ± 0.0472 |
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
| cells * 10^9/L | Adalimumab 40 mg EOW/EW |
|---|---|
| Red blood cell count | 0.03 ± 0.416 |
| Platelet count | -10.5 ± 96.98 |
| White blood cell count | 0.41 ± 2.704 |
| Neutrophils | 0.164 ± 2.4225 |
| Lymphocytes | 0.155 ± 0.8270 |
| Monocytes | 0.051 ± 0.2203 |
| Eosinophils | 0.002 ± 0.1602 |
| Basophils | 0.009 ± 0.0586 |
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
| U/L | Adalimumab 40 mg EOW/EW |
|---|---|
| Alanine aminotransferase | 3.7 ± 22.03 |
| Aspartate aminotransferase | 2.6 ± 28.13 |
| Alkaline phosphatase | -0.2 ± 34.65 |
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
| μmol/L | Adalimumab 40 mg EOW/EW |
|---|---|
| Total bilirubin | -1.0 ± 5.35 |
| Creatinine | 2.4 ± 13.18 |
| Uric acid | 7.6 ± 65.52 |
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
| mmol/L | Adalimumab 40 mg EOW/EW |
|---|---|
| Blood urea nitrogen | 0.32 ± 1.409 |
| Inorganic phosphate | -0.003 ± 0.2312 |
| Calcium | -0.012 ± 0.1185 |
| Sodium | -0.0 ± 2.49 |
| Potassium | 0.07 ± 0.424 |
| Glucose | 0.05 ± 1.334 |
| Cholesterol | -0.025 ± 0.8853 |
| Triglycerides | 0.178 ± 1.2800 |
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
| g/L | Adalimumab 40 mg EOW/EW |
|---|---|
| Albumin | -0.4 ± 3.85 |
| Total protein | 0.7 ± 18.99 |
Blood samples for laboratory tests were performed at each study visit after questionnaires and vital sign determinations.
| mg/L | Adalimumab 40 mg EOW/EW |
|---|---|
| Clinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein | 0.382 ± 15.1489 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 398 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 40 mg EOW/EW | — | 158/592 (26.7%) | 391/592 (66%) |
| Event | Adalimumab 40 mg EOW/EW |
|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 34/592 |
| PNEUMONIAInfections and infestations | 11/592 |
| ANAEMIABlood and lymphatic system disorders | 6/592 |
| APPENDICITISInfections and infestations | 5/592 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 5/592 |
| COLITISGastrointestinal disorders | 3/592 |
| ANAL ABSCESSInfections and infestations | 3/592 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 3/592 |
| B-CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/592 |
| UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/592 |
| Event | Adalimumab 40 mg EOW/EW |
|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 180/592 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 115/592 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 62/592 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 58/592 |
| SINUSITISInfections and infestations | 53/592 |
| DIARRHOEAGastrointestinal disorders | 46/592 |
| HEADACHENervous system disorders | 46/592 |
| INFLUENZAInfections and infestations | 42/592 |
| RASHSkin and subcutaneous tissue disorders | 42/592 |
| COUGHRespiratory, thoracic and mediastinal disorders | 41/592 |
ITT-1: All subjects who received ≥1 dose of study drug excluding 7 subjects at noncompliant sites.
| Age, Continuous(years) | Adalimumab 40 mg EOW/EW |
|---|---|
| Mean | 41.6 ± 12.85 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg EOW/EW |
|---|---|
| Female | 214 |
| Male | 371 |
No study locations are listed for this record.
Ran from Nov 2007 to primary completion in Dec 2016, 109 months.
Results were first posted in Dec 2017, 1 year after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 109 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →